Harbin Pharmaceutical Group Co Ltd (600664) — Cash Flow Quality Index
Harbin Pharmaceutical Group Co Ltd (600664) has a Cash Flow Quality Index of -2.79x as of September 2025. Operating cash flow of CN¥-192.19 Million is below net income of CN¥68.89 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Harbin Pharmaceutical Group Co Ltd (600664) long-term investment share to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Harbin Pharmaceutical Group Co Ltd Cash Flow Quality Index (1998–2024)
Historical Cash Flow Quality Index for Harbin Pharmaceutical Group Co Ltd across 26 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 600664 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Harbin Pharmaceutical Group Co Ltd (1998–2024)
Year-by-year earnings quality comparison for Harbin Pharmaceutical Group Co Ltd. For live market cap and the full company financial profile, see 600664 market cap overview.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.15x | CN¥792.50 Million | CN¥690.61 Million | ▼ -52.2% |
| 2023 | 2.40x | CN¥949.67 Million | CN¥395.26 Million | ▲ +97.4% |
| 2022 | 1.22x | CN¥622.09 Million | CN¥511.09 Million | ▲ +407.1% |
| 2021 | -0.40x | CN¥-162.44 Million | CN¥409.85 Million | ▲ +83.0% |
| 2019 | -2.34x | CN¥-284.94 Million | CN¥121.87 Million | ▼ -236.2% |
| 2018 | 1.72x | CN¥692.72 Million | CN¥403.63 Million | ▲ +434.1% |
| 2017 | 0.32x | CN¥149.22 Million | CN¥464.36 Million | ▼ -90.2% |
| 2016 | 3.29x | CN¥2.78 Billion | CN¥843.80 Million | ▲ +21.9% |
| 2015 | 2.70x | CN¥1.66 Billion | CN¥614.48 Million | ▼ -53.0% |
| 2014 | 5.75x | CN¥1.14 Billion | CN¥197.68 Million | ▲ +454.0% |
| 2013 | 1.04x | CN¥141.64 Million | CN¥136.53 Million | ▲ +9.7% |
| 2012 | 0.95x | CN¥557.83 Million | CN¥590.03 Million | ▲ +1840.9% |
| 2011 | -0.05x | CN¥-31.56 Million | CN¥581.22 Million | ▼ -105.3% |
| 2010 | 1.02x | CN¥1.15 Billion | CN¥1.13 Billion | ▼ -48.7% |
| 2009 | 1.98x | CN¥1.85 Billion | CN¥933.59 Million | ▲ +196.0% |
| 2008 | 0.67x | CN¥578.59 Million | CN¥863.65 Million | ▼ -39.0% |
| 2007 | 1.10x | CN¥650.16 Million | CN¥592.25 Million | ▼ -14.5% |
| 2006 | 1.28x | CN¥738.08 Million | CN¥575.16 Million | ▼ -8.7% |
| 2005 | 1.41x | CN¥757.76 Million | CN¥538.90 Million | ▲ +157.5% |
| 2004 | 0.55x | CN¥149.01 Million | CN¥272.83 Million | ▼ -36.8% |
| 2003 | 0.86x | CN¥302.83 Million | CN¥350.57 Million | ▼ -30.0% |
| 2002 | 1.23x | CN¥383.44 Million | CN¥310.55 Million | ▼ -40.2% |
| 2001 | 2.07x | CN¥604.13 Million | CN¥292.44 Million | ▼ -12.6% |
| 2000 | 2.36x | CN¥541.70 Million | CN¥229.07 Million | ▼ -13.4% |
| 1999 | 2.73x | CN¥431.22 Million | CN¥157.91 Million | ▲ +64.4% |
| 1998 | 1.66x | CN¥221.41 Million | CN¥133.33 Million | — |